In cystic cholangiocytes, SBI-115 plus pasireotide reduced cAMP, proliferation and cyst growth by approximately 50%, versus approximately 30% with SBI-115 alone.
In plain wordsIn cells, SBI-115 plus pasireotide reduced cAMP, cell proliferation and cyst growth more than SBI-115 alone.
- Peptide
- Pasireotide
- Outcome
- DecreasecAMP, cell proliferation and cyst growth
- Study
n: not reported in source
Cystic cholangiocytes- Comparator
- SBI-115 alone
- Outcome group
- Receptor activity and mechanism · Liver
- Studied dose
- Dose not stated
Source sentences
Levels of cAMP, cell proliferation, and cyst growth in vitro were decreased by ∼30% in cystic cholangiocytes after treatment with SBI-115 alone and by ∼50% when SBI-115 was combined with pasireotide.
1 context sentence(design, population, supporting numbers)
In vitro, we assessed cholangiocyte proliferation, cAMP levels, and cyst growth in response to (1) TGR5 agonists (taurolithocholic acid, oleanolic acid [OA], and two synthetic compounds), (2) a novel TGR5 antagonist (m-tolyl 5-chloro-2-[ethylsulfonyl] pyrimidine-4-carboxylate [SBI-115]), and (3) a c…